scholarly article | Q13442814 |
P50 | author | Alberto Bardelli | Q28321691 |
Andrea Sartore-Bianchi | Q28321693 | ||
Salvatore Siena | Q28321703 | ||
Paolo M. Comoglio | Q37381902 | ||
Andrea Bertotti | Q37831180 | ||
Silvio Marco Veronese | Q39051644 | ||
Silvia Marsoni | Q42882462 | ||
Daniele Regge | Q43198572 | ||
Angelo Vanzulli | Q43295970 | ||
Sara Lonardi | Q50876272 | ||
Francesca Bergamo | Q52682305 | ||
Giulia Siravegna | Q56862949 | ||
Vittorina Zagonel | Q56925944 | ||
Ilaria Depetris | Q56999753 | ||
Cosimo Martino | Q61307821 | ||
A Amatu | Q82728305 | ||
Francesco Leone | Q88197017 | ||
Livio Trusolino | Q88370775 | ||
Valter Torri | Q90627606 | ||
Patrizia Racca | Q115139909 | ||
Katia Bencardino | Q117279618 | ||
Calogero Lauricella | Q117805144 | ||
P2093 | author name string | Fortunato Ciardiello | |
Emanuele Valtorta | |||
Silvia Ghezzi | |||
Giovanna Marrapese | |||
Teresa Troiani | |||
Erika Martinelli | |||
Laura Palmeri | |||
Andrea Cassingena | |||
P2860 | cites work | Cancer genome landscapes | Q22242276 |
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 | ||
Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients | Q27852057 | ||
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study | Q28238311 | ||
The meaning and use of the area under a receiver operating characteristic (ROC) curve | Q29547182 | ||
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests | Q30496268 | ||
Evaluating the yield of medical tests | Q34277948 | ||
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer | Q34501536 | ||
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils | Q36038823 | ||
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer | Q36432094 | ||
The genomic landscape of response to EGFR blockade in colorectal cancer. | Q36930106 | ||
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer | Q37378581 | ||
Biomarkers of drugs targeting HER-family signalling in cancer. | Q38150774 | ||
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution | Q38257912 | ||
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Q38384113 | ||
Metastatic colorectal cancer: current state and future directions | Q38445676 | ||
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas. | Q38841950 | ||
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial | Q40931820 | ||
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. | Q41735415 | ||
Randomized trial of TAS-102 for refractory metastatic colorectal cancer | Q41741632 | ||
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial | Q45217739 | ||
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. | Q45938699 | ||
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study | Q46465639 | ||
Sample size tables for exact single-stage phase II designs | Q47216643 | ||
A 21-year-old patient with a HER2-positive colorectal cancer. | Q53038276 | ||
Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer | Q84419743 | ||
P433 | issue | 6 | |
P921 | main subject | trastuzumab | Q412616 |
multicenter clinical trial | Q6934595 | ||
colorectal cancer | Q188874 | ||
colorectal carcinoma | Q25493920 | ||
phase II clinical trial | Q42824440 | ||
metastatic colon cancer | Q108566365 | ||
P304 | page(s) | 738-746 | |
P577 | publication date | 2016-06-01 | |
P1433 | published in | Lancet Oncology Commission | Q13747613 |
P1476 | title | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | |
P478 | volume | 17 |
Q90843197 | A practical guide to biomarkers for the evaluation of colorectal cancer |
Q90702699 | A systematic review of salvage therapies in refractory metastatic colorectal cancer |
Q52371842 | Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. |
Q93159538 | Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer |
Q38650454 | Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. |
Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
Q91622958 | Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma |
Q89746060 | BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors |
Q39453583 | Biologics in bowel cancer |
Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
Q55113382 | Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. |
Q64250623 | CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy |
Q27612411 | CIViC database |
Q39012229 | Cancer predisposition syndromes: lessons for truly precision medicine |
Q91742610 | Circulating tumor DNA in colorectal cancer: opportunities and challenges |
Q91892015 | Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes |
Q54980136 | Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. |
Q102059072 | Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab |
Q41545171 | Clinical utility of circulating cell-free DNA in advanced colorectal cancer |
Q64229063 | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
Q90834049 | Colorectal cancer |
Q55306266 | Colorectal cancer genomics and designing rational trials. |
Q55411157 | Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. |
Q92522562 | Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models |
Q93128612 | Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer |
Q52603962 | Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. |
Q46185591 | Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. |
Q60926921 | Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study |
Q54976942 | Composite regulation of ERK activity dynamics underlying tumour-specific traits in the intestine. |
Q90699218 | Comprehensive review of targeted therapy for colorectal cancer |
Q91704285 | Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material |
Q39066439 | Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer |
Q50105696 | Copy number profiles of paired primary and metastatic colorectal cancers |
Q40411498 | Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer |
Q92256962 | Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC) |
Q89993964 | Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research |
Q38787244 | Current and future biomarkers in the treatment of colorectal cancer. |
Q90437250 | Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer |
Q39172118 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie |
Q99406919 | Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm |
Q64076253 | Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort |
Q33898865 | Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. |
Q47437634 | Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study. |
Q50893422 | Development of Phosphorothioate DNA and DNA Thioaptamers. |
Q57183898 | Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status |
Q92150346 | Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma |
Q90392916 | Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab |
Q58783221 | Eastern Canadian Colorectal Cancer Consensus Conference 2017 |
Q52668202 | Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. |
Q38941928 | Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer |
Q58106214 | Enrichment of Amplification in Brain Metastases from Primary Gastrointestinal Malignancies |
Q92185841 | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer |
Q33607015 | FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance |
Q53702883 | First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. |
Q38786707 | From tumour heterogeneity to advances in precision treatment of colorectal cancer |
Q91904078 | Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains |
Q38676702 | Genetic and epigenetic markers in colorectal cancer screening: recent advances |
Q64235344 | Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival |
Q90643842 | Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy |
Q90257585 | Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer |
Q50115014 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers |
Q37708897 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives |
Q92885759 | HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer |
Q89868898 | HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China |
Q90593024 | HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features |
Q90242172 | HER2-targeted therapies - a role beyond breast cancer |
Q49832628 | Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus. |
Q41548672 | Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient |
Q92830547 | Immunohistochemistry-Enabled Precision Medicine |
Q92316369 | Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer |
Q91666453 | Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance) |
Q90292724 | Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors |
Q47132740 | Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test |
Q64994221 | Importance of genetic screens in precision oncology. |
Q55116636 | In the literature: May 2016. |
Q52648328 | Inhibition of Wntless/GPR177 suppresses gastric tumorigenesis. |
Q39095733 | Interrogating open issues in cancer precision medicine with patient-derived xenografts. |
Q42925962 | Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors |
Q64947645 | Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. |
Q52592641 | MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. |
Q55032398 | Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). |
Q28076490 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer |
Q58754996 | Membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies |
Q59803127 | Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy |
Q91831000 | Metastatic colorectal cancer: therapeutic options for treating refractory disease |
Q97587469 | Modern therapeutic approaches for the treatment of malignant liver tumours |
Q90644223 | Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment? |
Q58700723 | Molecular Diagnostics in Clinical Oncology |
Q88541726 | Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer |
Q37710556 | Molecular Testing for Gastrointestinal Cancer. |
Q59794745 | Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream |
Q50037194 | Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases |
Q28076360 | Molecular pathology of cancer: how to communicate with disease |
Q91786652 | Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy |
Q41091941 | Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience |
Q98386286 | Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer |
Q91689913 | Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis |
Q38690672 | Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies |
Q38376337 | Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers |
Q90190001 | Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy |
Q50089419 | Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study |
Q55518643 | Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma. |
Q92912017 | Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal |
Q55342871 | Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. |
Q91831006 | Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond |
Q89782341 | PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma |
Q53360410 | POLE mutations in colorectal cancer: a new biomarker? |
Q92280751 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study |
Q38679229 | Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment |
Q39223563 | Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. |
Q38698206 | Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience |
Q64903410 | Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy. |
Q92841164 | Precision medicine for gastrointestinal cancer: Recent progress and future perspective |
Q92280765 | Precision oncology giveth and precision oncology taketh away |
Q39453559 | Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment |
Q38648300 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets |
Q90513170 | Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer |
Q38816712 | Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. |
Q88646346 | Promising New Agents for Colorectal Cancer |
Q49796158 | Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report |
Q38803202 | Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. |
Q57821644 | Recent advances in understanding colorectal cancer |
Q41105389 | Recent developments in the treatment of metastatic colorectal cancer. |
Q93375221 | Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial |
Q94076600 | Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PE |
Q92381922 | Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018 |
Q64239421 | Revisiting Epidermal Growth Factor Receptor () Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies |
Q39455125 | Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis |
Q28068817 | Role of targeted therapy in metastatic colorectal cancer |
Q90711036 | Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study |
Q64114423 | Selecting treatment options in refractory metastatic colorectal cancer |
Q55088555 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. |
Q92526836 | Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response |
Q90724422 | Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy |
Q91291948 | Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients |
Q48219440 | Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. |
Q42385734 | Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape |
Q38961110 | Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. |
Q90183323 | Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer |
Q49417294 | Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine |
Q41340207 | Targeted therapies for gastric cancer: failures and hopes from clinical trials |
Q37743048 | Targeted therapies in breast cancer: New challenges to fight against resistance |
Q92747984 | Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer |
Q99408604 | Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications |
Q48234912 | Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. |
Q30315224 | Targeting HER2: precision oncology for colorectal cancer |
Q54962247 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. |
Q57175806 | The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies |
Q64229129 | The Developing Story of Predictive Biomarkers in Colorectal Cancer |
Q92193162 | The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer |
Q95841155 | The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review |
Q42699046 | The SHIVA01 trial: what have we learned? |
Q92181246 | The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases |
Q58799989 | The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer |
Q92462230 | The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer |
Q64065309 | The landscape of d16HER2 splice variant expression across HER2-positive cancers |
Q92785578 | The past, present, and future of HER2 (ERBB2) in cancer: Approaches to molecular testing and an evolving role in targeted therapy |
Q42139529 | Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation |
Q28071772 | Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence |
Q90711354 | Towards the era of precision medicine in metastatic colorectal cancer |
Q30239109 | Translating genomic profiling to gastrointestinal cancer treatment |
Q47560949 | Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer |
Q28077666 | Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives |
Q64117310 | Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies |
Q88608605 | Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program |
Q64262617 | Update on systemic therapy for colorectal cancer: biologics take sides |
Q97644005 | Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019 |
Q89326750 | Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma |
Q39306576 | What We Know About Stage II and III Colon Cancer: It's Still Not Enough |
Q97424206 | ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper |
Search more.